PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bmccancBioMed Centralsearchsubmit a manuscriptregisterthis articleBMC Cancer
 
BMC Cancer. 2012; 12: 210.
Published online May 31, 2012. doi:  10.1186/1471-2407-12-210
PMCID: PMC3489567
Has the time to come leave the “watch-and-wait” strategy in newly diagnosed asymptomatic follicular lymphoma patients?
Antonio Rueda,corresponding author1 María Casanova,1 Maximino Redondo,2 Elisabeth Pérez-Ruiz,1 and Ángeles Medina-Pérez1
1Department of Oncology, Hospital Costa del Sol, Marbella, Spain
2Biochemistry, Hospital Costa del Sol, Marbella, Spain
corresponding authorCorresponding author.
Antonio Rueda: arueda/at/hcs.es; María Casanova: mariacasanova/at/yahoo.com; Maximino Redondo: mredondo/at/hcs.es; Elisabeth Pérez-Ruiz: eliperu/at/gmail.com; Ángeles Medina-Pérez: amedinaperez/at/gmail.com
Received December 5, 2011; Accepted May 14, 2012.
Abstract
Background
Historically, the median overall survival for follicular lymphoma (FL) has been considered to be 9-10 years, and no treatment had ever prolonged this time period. Studies conducted more than 20 years ago demonstrated that treating patients with asymptomatic FL at the onset of the disease did not increase their survival, and that almost 20% of these patients did not need any treatment in the first 10 years of follow-up. Based on these facts, most clinical practice guidelines recommend active surveillance policies for patients with asymptomatic FL.
Discussion
The introduction of antiCD-20 monoclonal antibodies, over the last 15 years, has significantly increased the median survival rate to above 14 years. This improvement was achieved before the combination of rituximab and chemotherapy regimens became extensively used in patients with symptomatic disease. Therefore, this increase in survival may currently be more significant. At present, several clinical trials have evaluated low-toxicity therapies that prolong progression-free periods, among which rituximab monotherapy, radioimmunotherapy or the combination of rituximab with bendamustine are the most relevant. Unfortunately, these clinical trials have included only patients with symptomatic FL. The results of a recently reported clinical trial show that treatment with single-agent rituximab prolongs progression-free survival rates, time to new treatment and the quality of life of asymptomatic patients, as compared with the active surveillance strategy. Longer follow-up of these results and data regarding overall survival are awaited before this treatment can be recommended as the standard initial therapy.
Summary
There are different therapeutic possibilities for asymptomatic FL patients, but no data are currently available to indicate which option is the best. Patients need to understand the risks and benefits of observation versus treatment before a final decision can be made. For patients who want active treatment the administration of four weekly rituximab doses should be considered.
Articles from BMC Cancer are provided here courtesy of
BioMed Central